10-K
Annual Report
Translational Development Acquisition Corp. TDAC TDACU TDACW
0001104659-26-036811
- Filed
- Mar 30, 2026 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Operating Cash Flow | FY 2025 · Dec 31, 2025 | −$608.39K |
| Operating Cash Flow | FY 2025 · Dec 31, 2024 | −$851.45K |
| Cash And Equivalents | FY 2025 · Dec 31, 2025 | $29.79K |
| Cash And Equivalents | FY 2025 · Dec 31, 2024 | $438.17K |
| Stockholders Equity | FY 2025 · Dec 31, 2025 | −$6.54M |
| Stockholders Equity | FY 2025 · Dec 31, 2024 | −$5.6M |
| Stockholders Equity | FY 2025 · Dec 31, 2023 | −$507.66K |
| Current Liabilities | FY 2025 · Dec 31, 2025 | $544.07K |
| Current Liabilities | FY 2025 · Dec 31, 2024 | $210.3K |
| Total Liabilities | FY 2025 · Dec 31, 2025 | $6.58M |
| Total Liabilities | FY 2025 · Dec 31, 2024 | $6.25M |
| Current Assets | FY 2025 · Dec 31, 2025 | $39.47K |
| Current Assets | FY 2025 · Dec 31, 2024 | $650.23K |
| Total Assets | FY 2025 · Dec 31, 2025 | $181.7M |
| Total Assets | FY 2025 · Dec 31, 2024 | $175M |
| Sga Expense | FY 2025 · Dec 31, 2025 | $944.54K |
| Sga Expense | FY 2025 · Dec 31, 2024 | $196.36K |
| Net Income | FY 2025 · Dec 31, 2025 | $6.36M |
| Net Income | FY 2025 · Dec 31, 2024 | −$71.01K |
| Operating Income | FY 2025 · Dec 31, 2025 | −$944.54K |
| Operating Income | FY 2025 · Dec 31, 2024 | −$196.36K |